Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal polymerized Phleum pratense immunotherapy for grass pollen allergic rhinoconjunctivitis
2014-000429-18Phase 2Completed
- Sponsor
- Laboratorios Diater
- Start
- Mar 2014
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and asthma comparing Polymerized Phleum pratense intradermal immunotherapy with Placebo (2 arms). Primary endpoints: Assessment of efficacy of intradermally administered polymerized Phleum pratense immunotherapy and Combined symptom and medication score. Started Mar 2014; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2014-000429-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000429-18.